Race does not appear to be a prognostic factor for skeletal-related events (SRE) in bone metastatic castration-resistant prostate cancer (mCRPC), according to new study findings presented during the American Urological Association 2020 Virtual Experience.
Of 837 patients with bone metastases from mCRPC from 8 Veterans Affairs Medical Centers, 27.7% were black. Black men were significantly more likely to have higher PSA levels (41.7 vs 29.2 ng/mL), a longer time from CRPC to metastasis diagnosis (17.9 vs 14.3 months), and 10 or more bone metastases than nonblack men (29% vs 19%). Nonetheless, multivariable analysis showed that black men did not have a significantly higher risk of SREs or death, Devin Patel, MD, of the University of California, San Diego, and collaborators reported.
“We observed no association between racial differences and the development of SREs and overall mortality, indicating that once men have a diagnosis of bone mCRPC, race may not be a prognostic factor.”
Patel D, Howard L, Amling C, et al. Race does not predict skeletal-related events and all-cause mortality in men with castrate resistant prostate cancer. Presented at the America Urological Association 2020 Virtual Experience, May 15-19, 2020. Abstract PD16-10.
This article originally appeared on Renal and Urology News